Chief Financial Officer Luke Power said clinical volume growth and pricing both contributed to the performance. Its blended base average selling price surpassed $3,850, a company record, according to Power. Management said it expects the tissue-and-blood mix to remain broadly consistent with the second quarter in the back half of the year. New Assays and Pipeline ProgramsDuring the quarter, Caris launched ChromoSeq, a hematology therapy-selection assay using whole-genome and whole-transcriptome technology. About Caris Life Sciences (NASDAQ:CAI)Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology.